Skip to content

The Impact and Cost-effectiveness of Safer Conception Strategies for HIV-discordant Couples (SAFER)

The Impact and Cost-effectiveness of Safer Conception Strategies for HIV-discordant Couples

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03049176
Acronym
SAFER
Enrollment
46
Registered
2017-02-09
Start date
2017-03-13
Completion date
2019-07-31
Last updated
2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

HIV-discordant couple, ART, PrEP, semen washing, artificial vaginal insemination, safer conception, pregnancy

Brief summary

This is a prospective, non-randomized, open-label study to look at the uptake, adherence to, and impact of pre-exposure prophylaxis (PrEP), antiretroviral therapy (ART), semen washing, and vaginal insemination to prevent HIV among HIV-discordant couples attempting conception in Zimbabwe.

Detailed description

The reproductive needs of HIV-discordant couples who desire pregnancy represent an urgent public health problem that has been neglected in HIV prevention research. In Zimbabwe , and across sub-Saharan Africa, the vast majority of HIV-infected individuals are adults of reproductive age. Pregnancy and the desire for children are common among HIV-infected individuals, and HIV-discordant couples face a difficult choice between attempting pregnancy and risking HIV transmission to their partners. Recent surveys have found that 30-50% of HIV-infected individuals in sub-Saharan Africa are involved in stable, HIV-discordant relationships, and HIV transmission within married, cohabitating HIV-discordant couples accounts for 44-60% of new HIV infections in some regions of sub-Saharan Africa. While knowledge of HIV discordance can lead to increased condom use, many discordant couples have unprotected intercourse often motivated by the desire to conceive. Currently, HIV discordant couples who attempt to conceive place themselves at considerable risk of transmission. This research study aims to help promote couples' rights to conceive while at the same time decreasing the risk of HIV transmission.

Interventions

DRUGPrEP (Truvada)

oral, daily Truvada for HIV-negative participants

oral daily antiretrovirals and frequent viral load monitoring for HIV-positive participant

PROCEDURESemen washing

collection of semen from an HIV-positive man, processing semen to remove HIV, followed by intrauterine insemination

PROCEDUREArtificial vaginal insemination

collection of semen from an HIV-negative man, followed by intravaginal insemination

Sponsors

UZ-UCSF Collaborative Research Programme
CollaboratorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH
Gilead Sciences
CollaboratorINDUSTRY
University of California, San Francisco
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

For all couples: * Couple expresses a desire to conceive * Sexually active (defined as having vaginal sex with one another at least 6 times in the past 3 months * Willing to enter the study as a couple and intending to remain as a couple and have a sexual relationship for the next 12 months * Willing to use at least one safer conception strategy * For men, age ≥18 years. For women, age 18 - 35 years; * Able and willing to provide written informed consent For HIV-uninfected members of the couple * HIV-negative based on parallel negative HIV rapid tests, both at study screening and enrollment visit * Adequate renal function, defined by normal creatinine levels and estimated creatinine clearance ≥60 mL/min For HIV-infected members of the couple * HIV-positive based on parallel positive HIV rapid tests, based on national algorithm * No current AIDS-defining illness

Exclusion criteria

* Amenorrheic * Currently pregnant * Active and serious infections, including active tuberculosis infection; active clinically significant medical problems including cardiac disease, pulmonary disease, and previously diagnosed malignancy expected to require further treatment. * History of infertility defined as a year or more of regular unprotected intercourse with current partner without pregnancy, or otherwise medically diagnosed infertility * Currently on any concomitant medication that requires the participant to avoid use of PrEP

Design outcomes

Primary

MeasureTime frameDescription
Uptake of safer conception strategies12 monthsproportion of couples choosing the strategy
Acceptability of safer conception strategies12 monthsproportion of couples remaining on strategy; reports of satisfaction
Adherence to safer conception strategies12 monthsproportion of couples with high adherence to strategy

Secondary

MeasureTime frameDescription
Effectiveness of safer conception strategies on HIV prevention12 monthsincidence of HIV
cost-effectiveness of safer conception strategies12 monthsmodel the cost effectiveness of various combinations of safer conception strategies
Effectiveness of safer conception strategies on achieving pregnancy12 monthsincidence of pregnancy
costs of providing safer conception services12 monthscosts

Countries

Zimbabwe

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026